Background
==========

Hospital standardised mortality ratios (HSMRs) are widely used as an indicator to assess and improve the quality of care. HSMRs have been calculated in the UK, USA, Canada, Australia and the Netherlands \[[@B1]\]. HSMR outcomes fluctuate around 100. For example in the UK the outcomes range from 72 to 118 and in the Netherlands from 62 to 142 \[[@B1],[@B2]\]. The Dutch HSMR model was developed by the Dr. Foster Intelligence Unit in London in co-operation with Kiwa Prismant in the Netherlands. The model adjusts for patient casemix factors including age, sex and diagnostic group. It is based upon the national medical registration data (LMR). In October 2010 the \'Dutch Hospital Data\' group (DHD) distributed the hospital specific, \'H/SMR report 2007-2009 with detailed information on diagnostic groups and patient categories\', among Dutch hospitals. In this way, each hospital obtained an insight into their own standardised mortality ratios (SMRs) for 50 diagnostic groups and had the opportunity to work on improving patient safety.

HSMRs are also made publicly available in countries, for example in the UK\'s \'2010 Dr Foster Hospital Guide\'\[[@B2]\]. However questions have been raised about how reliable, valid and applicable the model really is \[[@B3]-[@B10]\]. It is still not clear to what degree the current HSMR and SMR outcomes are attributable to quality of care and can be used to make a meaningful comparison between hospitals. Bottle et al claim however that variations in adjustment methods have a limited impact on the hospitals position relative to funnel plot control limits \[[@B11]\].

One type of potential distortion in establishing comparable HSMRs is caused by the failure to adjust for variations in readmission frequencies. Van den Bosch, et al \[[@B10]\] have demonstrated that the Dutch 2010 HSMR model favoured hospitals with relatively many frequently readmitted patients, regardless of disease, compared to hospitals with many patients who are not frequently readmitted. They were, however, not able to quantify the effect of this upon the HSMR, because the study was restricted to only six hospitals. In a new study more data was made available enabling us to quantify the possible effect in the Netherlands. We were able to compare the HSMR outcomes of the current HSMR model to an alternative model with an additional adjustment for readmission frequency. In essence we asked: Does the new model represent an improvement in the current model, based on c-statistics, goodness of fit and explanatory power? And if so, to what extent do HSMR and SMR outcomes differ, comparing model 1 to model 2?

Methods
=======

Setting
-------

For the purpose of this model analysis the DHD group gave its formal permission to use an anonymised LMR dataset from 89 Dutch hospitals covering the years 2005 to 2009. Nineteen hospitals were excluded from the calculation because the quality of their patient registration data was insufficient.

This study excluded any experimental research, either on human or animal subjects.

The HSMR model used in this study
---------------------------------

We performed HSMR calculations using two models, shown as model 1 and model 2.

For *model 1*, we used the Dr Foster model \[[@B1]\], applied in the Netherlands in 2010. This Dutch model included clinical admissions only, so no day cases. Furthermore only *in-hospital*deaths were counted. There are differences between the Dutch and the UK model. The Dutch model used 50 Clinical Classifications Software (CCS) groups based on an ICD-9 coding, whereas the UK used 56 CCS groups based on ICD-10 coding, of which 42 groups were the same as in the Dutch model. Furthermore, the UK model adjusted for palliative care and for the number of previous emergency admissions within one year. The Dutch model did not adjust for either of these.

HSMR in brief
-------------

The ***HSMR (\'hospital standardised mortality ratio\')***is the ratio between the observed number of in-hospital deaths and the predicted number of deaths, determined by comparing the patient casemix with the national average. The outcome is standardised around 100. A value above 100 indicates higher mortality than average, below 100, lower mortality. If the calculation is applied to one of the 50 diagnostic groups, then we speak of the SMR (\'standardised mortality ratio\').

The Dutch HSMR model of 2010 adjusts for the following **casemix properties**: year of discharge, sex, age at admission, admission type, comorbidity (charlsonindex), social deprivation, month of admission, source of referral, diagnostic group, and, in part, for the casemix on the primary diagnostic level.

Each **diagnostic group**is composed of a number of underlying diseases: ICD-9 codes (International Classification of Diseases Ninth edition) as determined by the Clinical Classification Software (CCS). This tool clusters various ICD-9 diagnoses into a manageable number of meaningful categories \[[@B12]\], indicated as \'CCS diagnostic groups\'. The selected CCS diagnostic groups have a relatively high mortality and together cover over 80% of the total number of hospital deaths.

For *model 2*, we took model 1 and added an adjustment for the frequency of readmission, as described by Van den Bosch WF, et al \[[@B10]\]. The authors demonstrated that frequently admitting patients was associated with lower mortality ratios *per admission*, for which an additional correction would be needed. In their publication the patients were grouped into \'patient view\' classes P(m). We have also applied this to our study. Here the admission frequency m was equal to the number of times a patient was admitted to the same hospital during the five-year study period.

For example, a patient who was admitted ten times during the five-year period to hospital X, to be treated for one or more diseases, possibly with different diagnoses, was part of the patient view class P(10) and not part of any other patient view class. This patient contributed ten admissions to P(10) which were all accounted for in the regression calculation.

We were able to retrieve the number of times that a patient was admitted through the unique patient identification number that all of the 70 hospitals included were using. We have grouped the patient view classes into eight categories: m = 1, m = 2, m = 3, m = 4, m = 5-6, m = 7-9, m = 10-20 and m \> 20. This is in order to limit the number of categories for the regression calculation and to avoid categories becoming too small.

Agreement, or otherwise of the two models
-----------------------------------------

We have calculated to what extent both models did agree, or did not agree, as follows:

1\. *Relative change*. To what extent did SMR~model\ 1~differ from SMR~model\ 2~per CCS diagnostic group, per hospital? Using the formula SMR~delta~= (SMR~model2~/SMR~model1~-1)\*100%, we calculated the shifts for all of the 3500 SMRs (50 diagnostic groups times, 70 hospitals), occurring when changing from model 1 to model 2. We represented these in a frequency distribution. In a similar way we have calculated and represented the 70 shifts that occurred for the HSMRs of the 70 hospitals. We also compared all pairs of death predictions of model 1 and model 2 per admission by calculating regressions coefficients (R^2^) on the SMR level and the HSMR level. These metrics were used as a measure of statistical \'distance\' between both models.

2\. *Significance scores*of SMRs and HSMRs. We determined per SMR how many hospitals with a significantly high SMR score according to model 1 turned out not to be significantly high according to model 2. And vice versa, in other words: how often a significantly high SMR score in model 2 turned out not to be a significantly high score in model 1. In a similar way we calculated these differences on the hospital level for HSMRs.

Quality metrics of the two models
---------------------------------

We have calculated and compared the quality metrics of the models with respect to:

1\. *Discrimination*, expressed in \'c-statistics\' on the SMR level and on the HSMR level. This statistical measure indicates how well a regression model is able to predict mortality. Each predicted outcome per admission is compared to the observed outcome: died or survived. A c-statistic of 0.5 has no predictive value: 50% right, 50% wrong. Values above 0.75 suggest good discrimination. A value of 1 is perfect. The overall c-statistic for the Dutch HSMR (model 1) scored above 0.85.

2\. *Calibration*, according to Hosmer and Lemeshow. This represents a statistical test for goodness-of-fit that is frequently used in risk prediction models. The test assesses whether or not the observed event rates match expected event rates in subgroups of the model population. The test specifically identifies subgroups as the deciles of fitted risk values. Models in which expected and observed event rates in subgroups are similar, are called well-calibrated \[[@B13]\].

3\. *Explanatory power*, using the pseudo R^2^statistic according to the \'Nagelkerke R square\', in order to assess the degree to which the additional adjustment for readmission changes the unexplained variance in the data.

Sensitivity of the HSMR model to adjustment for readmission
-----------------------------------------------------------

We have investigated to what extent the model was sensitive to variations in the length of the period under review. We took three scenarios: a period of review of one year (2009), two years (2008-2009) and five years (2005-2009). We then examined the statistical distance between model 1 and model 2, and the three model quality metrics on the HSMR level.

Results
=======

We analysed the data from 89 hospitals of which 19 were excluded because they had an incomplete registration of the patient identification numbers. Therefore, we included 70 hospitals for the regression calculation, a total of 2494613 admissions.

Agreement between the two models
--------------------------------

Figure [1](#F1){ref-type="fig"} shows the frequency distribution of the relative changes of the 3500 SMRs, in going from model 1 to model 2. Similarly the changes of the 70 HSMRs of the hospitals are shown in Figure [2](#F2){ref-type="fig"}. The SMR changes ranged from -39% to +110% and the HSMR changes ranged from -12% to +11%. The standard deviation of the frequency distribution of the changes amounted to 12.2% (roughly 12 SMR points) for the SMRs and to 4.1% (roughly 4 HSMR points) of the HSMRs.

![**Frequency distribution of relative changes of all 3500 SMRs when changing from model 1 (Dr Foster model) to model 2 (model with additional adjustment for readmission frequency)**. \* Standard deviation amounts to 12.2%.](1472-6963-12-91-1){#F1}

![**Frequency distribution of relative changes of the 70 HSMRs when changing from model 1 (Dr Foster model) to model 2 (model with additional adjustment for readmission frequency)**. \* Standard deviation amounts to 4.1%.](1472-6963-12-91-2){#F2}

Table [1](#T1){ref-type="table"} shows the agreement that we found between model 1 and model 2, expressed as a statistical distance per SMR. The R^2^coefficients varied from 0.60 (COPD) to 0.95 (intracranial injury). For the entire model the coefficient amounted to 0.86.

###### 

A comparison of SMR outcomes of model 1 and model 2

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  CCS\   CCS-diagnostic group title                            Number of admissions   Distance between\   Number of hospitals with\   c-statistic for               
  code                                                                                model 1\            SMR significantly high?                                   
                                                                                      and 2 (R^2^)                                                                  
  ------ ----------------------------------------------------- ---------------------- ------------------- --------------------------- ----------------- ----------- -----------
  2      Septicemia (except in labour)                         14647                  0.83                2                           1                 0.760       0.783

  12     Cancer of oesophagus                                  9703                   0.74                1                           3                 0.730       0.763

  13     Cancer of stomach                                     13945                  0.75                0                           2                 0.733       0.779

  14     Cancer of colon                                       45116                  0.77                2                           5                 0.773       0.814

  15     Cancer of rectum and anus                             22246                  0.72                1                           3                 0.771       0.817

  17     Cancer of pancreas                                    9950                   0.76                1                           0                 0.685       0.704

  19     Cancer of bronchus, lung                              76714                  0.75                4                           6                 0.792       0.822

  24     Cancer of breast                                      64126                  0.74                2                           1                 0.916       0.850

  29     Prostate cancer                                       24092                  0.76                3                           1                 0.886       0.865

  32     Cancer of bladder                                     44288                  0.71                1                           0                 0.872       0.874

  38     Non-Hodgkin\'s lymphoma                               19413                  0.69                0                           5                 0.802       0.841

  39     Leukaemias                                            12466                  0.77                0                           1                 0.781       0.820

  42     Secondary malignancies                                69303                  0.77                5                           4                 0.748       0.770

  44     Neoplasms unspec nature or uncertain behaviour        18982                  0.63                2                           1                 0.805       0.840

  50     Diabetes mellitus with complications                  36837                  0.74                1                           0                 0.824       0.846

  55     Fluid and electrolyte disorders                       29705                  0.81                0                           1                 0.795       0.824

  59     Deficiency and other anaemia                          48896                  0.61                0                           1                 0.756       0.802

  85     Coma, stupor and brain damage                         4286                   0.92                0                           0                 0.801       0.815

  96     Heart valve disorders                                 30708                  0.77                1                           2                 0.775       0.788

  100    Acute myocardial infarction                           91802                  0.72                1                           1                 0.740       0.781

  101    Coronary atherosclerosis and other heart disease      250183                 0.66                1                           2                 0.784       0.805

  103    Pulmonary heart disease                               26937                  0.78                0                           1                 0.754       0.776

  106    Cardiac dysrhythmias                                  174923                 0.72                1                           2                 0.828       0.860

  107    Cardiac arrest and ventricular fibrillation           8118                   0.89                2                           2                 0.739       0.764

  108    Congestive heart failure, non-hypertensive            108541                 0.63                4                           1                 0.637       0.702

  109    Acute cerebrovascular disease                         102295                 0.86                3                           0                 0.744       0.761

  114    Peripheral and visceral atherosclerosis               44090                  0.94                1                           3                 0.908       0.914

  115    Aortic, peripheral and visceral artery aneurysms      26538                  0.93                1                           1                 0.871       0.887

  116    Aortic & peripheral arterial embolism or thrombosis   32881                  0.75                1                           1                 0.882       0.892

  117    Other circulatory disease                             20452                  0.80                0                           1                 0.849       0.862

  122    Pneumonia                                             128867                 0.74                2                           0                 0.753       0.785

  127    COPD and bronchiectasis                               82898                  0.60                0                           2                 0.701       0.761

  129    Aspiration pneumonitis                                4485                   0.79                1                           1                 0.644       0.688

  130    Pleurisy, pneumothorax, pulmonary collapse            24798                  0.78                0                           0                 0.812       0.827

  133    Other lower respiratory disease                       99460                  0.77                1                           0                 0.854       0.866

  145    Intestinal obstruction without hernia                 34802                  0.76                1                           1                 0.813       0.836

  146    Diverticulosis and diverticulitis                     35917                  0.70                0                           0                 0.814       0.828

  149    Biliary tract disease                                 135587                 0.80                1                           0                 0.894       0.899

  150    Liver disease, alcohol-related                        5133                   0.69                0                           2                 0.678       0.758

  151    Other liver diseases                                  14584                  0.80                1                           0                 0.771       0.807

  153    Gastrointestinal haemorrhage                          37229                  0.71                0                           1                 0.738       0.764

  155    Other gastrointestinal disorders                      45487                  0.91                0                           0                 0.907       0.908

  157    Acute and unspecified renal failure                   8804                   0.73                0                           0                 0.723       0.760

  158    Chronic renal failure                                 14570                  0.75                0                           2                 0.846       0.872

  159    Urinary tract infections                              62382                  0.77                0                           0                 0.817       0.836

  226    Fracture of neck of femur (hip)                       74557                  0.73                0                           2                 0.719       0.732

  233    Intracranial injury                                   56535                  0.95                0                           1                 0.939       0.941

  237    Complication of device, implant or graft              76079                  0.69                0                           0                 0.821       0.833

  238    Complications surgical procedures or medical care     67106                  0.76                0                           0                 0.827       0.833

  249    Shock                                                 3150                   0.80                1                           0                 0.716       0.733

                                                                                                                                                                    

         Total all CCS diagnostic groups                       **2494613**            **0,86**            **49**                      **64**            **0.852**   **0.867**
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\* Per CCS diagnostic group: number of admissions; statistical distance between model 1 and model 2; number of hospitals with significance differences of SMRs comparing model 1 to model 2, c-statistics for both models. The table includes results of 70 Dutch hospitals over the period 2005 - 2009

Finally, we calculated per SMR for how many hospitals a significantly high SMR score changed to not significantly high from model 1 to model 2 and vice versa; see Table [1](#T1){ref-type="table"}. Model 1 indicated 328 SMRs in total as \"higher than expected\" of which 64 were not indicated by model 2 (20%). On the other hand, model 2 indicated 313 SMRs in total as \"higher than expected\" of which 49 were not indicated by model 1 (16%). Across hospitals, model 1 indicated that 23 hospitals recorded a higher than expected HSMR of which four were not indicated by model 2 (17%). And, alternatively, model 2 indicated that 23 hospitals were having a higher than expected HSMR of which four were not indicated by model 1 (17%).

H/SMR model quality metrics
---------------------------

For both models the \'c-statistic\' per CCS diagnostic group was calculated, see Table [1](#T1){ref-type="table"}. Model 2 scored a higher c-statistic compared to model 1 in 47 groups out of 50. For eighteen of these groups the scores of model 2 exceeded the scores of model 1 by between 0.03 and 0.08. Model 1 had one diagnostic group for which the c-statistic was at least 0.03 better compared to model 2. The c-statistic of the HMSR across all hospitals amounted to 0.852 for model 1 and to 0.867 for model 2 (favourable).

The results of the goodness-of-fit test are shown in Table [2](#T2){ref-type="table"}, expressed in the quality metrics of the Hosmer and Lemeshow test. It shows that model 2 was better calibrated compared to model 1: 7434 mismatches (5.75% of the total deaths) for model 1 compared to 5474 (4.23%) mismatches for model 2.

###### 

Contingency table with Hosmer and Lemeshow test for goodness-of-fit

                        Died model 1   Died model 2           
  --------------------- -------------- -------------- ------- -------
  1                     138            268            134     231
  2                     498            786            469     677
  3                     1057           1464           997     1295
  4                     1888           2485           1721    2197
  5                     3609           4038           3002    3544
  6                     6181           6399           5299    5599
  7                     10486          10026          8999    8843
  8                     16797          15578          14890   14337
  9                     28064          26026          27112   25084
  10                    60625          62273          66720   67535
                                                              
  Percentage mismatch   5,75%                         4,23%   

Finally the overall explanatory power expressed in pseudo R^2^statistics were calculated. These amounted to 0.259 for model 1 versus 0.282 for model 2 and so favourable to model 2.

Sensitivity of the model to the review period of adjustment
-----------------------------------------------------------

The overall agreement between models 1 and 2 varied, depending on the review period, from 0.92 (one year) to 0.89 (two years) to 0.86 (five years). So a longer review period corresponded with an increasing divergence between the two models.

Table [3](#T3){ref-type="table"} shows how the overall model quality metrics varied for the three review periods. A longer review period corresponded to an increase of model quality metric performance.

###### 

Comparison of HSMR model quality metrics of model 1 to model 2 for various lengths of review period

                                            Model 1   Model 2   Difference   In favour of
  ----------------------------------------- --------- --------- ------------ --------------
  1 year period                             0.857     0.866     0.009        model 2
  2 year period                             0.856     0.865     0.009        model 2
  5 year period                             0.852     0.867     0.015        model 2
                                                                             
  **% decile match hosmer lemeshow test**                                    
                                                                             
  1 y period                                93.85%    94.13%    0.28%        model 2
  2 year period                             93.82%    94.41%    0.59%        model 2
  5 year period                             94.25%    95.77%    1.52%        model 2
                                                                             
  **Nagelkerke R square**                                                    
                                                                             
  1 year period                             0.269     0.285     0.016        model 2
  2 year period                             0.266     0.284     0.018        model 2
  5 year period                             0.259     0.282     0.023        model 2

Discussion
==========

How should we interpret the differences in model outcomes?
----------------------------------------------------------

In this study we have calculated and compared the H/SMR outcomes of two models. The disagreement between the two models was substantial, according to the relative changes in HSMRs and SMRs.

The standard deviation of the frequency distribution of HSMR-change amounted to 4 HSMR points, which was substantial compared to the standard deviation of the HSMR-frequency distribution amounting to 14 HSMR points. Moreover, these shifts introduced an uncertainty into the HSMR outcomes that exceded the uncertainty due to chance as indicated by the 95% confidence intervals (CIs): The 95% CI of a HSMR equalled \[-2σ, 2σ\]. On average for the 70 hospitals over five years, the standard deviation σ of the CI distribution equalled 2.5 HSMR points.

With respect to the SMRs: the statistical \'distance\' between SMRs of model 1 and model 2 expressed in R^2^coefficients, varied from 0.60 to 0.95. Low scores indicated susceptibility to adjustment for readmissions. On average chronic diseases scored lower compared to acute diseases as to be expected since chronic diseases in particular often result in readmissions. There was no particular peak among any of the main diagnostic groups. The major diagnostic groups like cancer and heart and lung diseases all showed substantial disagreement between model 1 and model 2 due to adjustment for readmission. The results also showed disagreement between the models in designating hospitals as having higher than expected H/SMRs. The percentages of disagreement varied from 16% to 20%.

Bottom-line: all differences in H/SMR outcomes that we found between the two models, cannot be attributed to differences in the quality of care neither to \'chance\'. They have to be attributed to the difference in the type of model, because this is the only distinction applied in producing the results from the same set of admissions. This implies that publicised good and bad practices, linked to hospital rankings based on HSMRs, can differ substantially depending on the choice of model.

How do readmissions affect H/SMRs and how do they occur?
--------------------------------------------------------

We asked: how did readmissions impact the H/SMR, how did readmissions occur and why did hospitals differ in this respect?

For example: endlessly readmitting the same patient in the same hospital continuously increased the denominator (predicted death) of the calculated HSMR for that hospital. We have observed numerous cases where the contribution to the denominator on behalf of a single patient over the years aggregated to numerical values of 3 to 4. However a patient could only die once and so any patient could maximally contribute a numerical value of 1 to the numerator. Consequently this effect lowered the HSMR ratio and favoured hospitals which had many frequently readmitted patients.

There are many types of mechanisms that explain the variation in the frequency of clinical readmission. These could have been administrative in nature, for example differences in administrating chemotherapy \[[@B10]\]. There were also many systematic differences in treatment practice. For example one hospital applied and recorded a different number of clinical admissions than another hospital did for the same combination of diagnosis and treatment applied to the same patient. Differences also occurred as a consequence of transferring patients back and forth. Poor care during the initial admission may also have triggered readmissions later. As a consequence all these examples of increased readmissions were being \'rewarded\' by model 1 while model 2 was correcting for this phenomenon.

The analysis showed that the combined effect of all these mechanisms was not restricted to some of the diagnostic groups, but had an impact upon most of them. Clearly the HSMR model was susceptible to an adjustment for the frequency of readmissions in the way we have defined it.

The analysis also showed that reducing the review period from five to two years and from two to one year, resulted in a substantial reduction of this susceptibility. This phenomenon may be explained as follows: It may take several years before the readmissions of a patient constitute a substantial sequence of admissions. Furthermore a sequence might also have started long before the analysis period started. In these cases apparently one year was not a sufficiently long time period to capture sequences with a substantial amount of admissions. By looking at various years these sequences became better visible.

Choice of model: consequences for usage of H/SMR as indicator
-------------------------------------------------------------

We considered which of the two models would be more favourable to use and why. Since the model characteristics with regard to discrimination, calibration and explanatory power all were in favour of model 2, we recommend using model 2, although this preference does not necessarily invalidate model 1. HSMR models in other countries may need a similar additional adjustment. The impact of readmissions on the current HSMR in the UK is not clear. The UK model adjusts for readmissions for emergency cases. However for non-emergency cases the model does not adjust for readmissions. Moreover, admissions with different primary diagnoses are not counted as readmissions as well. Furthermore the UK model is restricted to a maximum review period of one year, which is too short for the readmission effect to become visible as demonstrated in our study.

A more fundamental issue than the choice of model however, is the fact that two comparable models, such as model 1 and model 2, may deliver such divergent outcomes. Since there is no \'gold standard\' one cannot state that the one is false and the other one is true. This finding reveals an uncertainty in HSMR outcomes that exceeds the amount of uncertainty introduced by chance expressed in 95% confidence intervals over the five-year period.

HSMRs and SMRs are increasingly used by physicians to improve the quality of care in their hospitals. In particular diagnostic groups with higher than expected mortality are the subjects of investigation. However, in a lot of cases, the designated significance of these groups may depend on the regression model used, not only on the confidence intervals. The same is applicable for the current HSMR scores in the Netherlands. Physicians and hospital managers should be aware of this phenomenon.

Limitations of the study
------------------------

A limitation of this study was the fact that we had to exclude 19 hospitals and so the HMSR calculation was based on roughly 80% of the Dutch hospitals. Nevertheless, we think the results of our study were representative of the Netherlands and have clearly demonstrated the impact upon the HSMR of not adjusting for frequency of readmissions.

Another limitation was the fact that the Dutch HSMR only accounts for in-hospital mortality and not for 30-day mortality, which may favour hospitals with shorter lengths of stay \[[@B14]\]. However since the effects, demonstrated in our study, particularly concerned the phenomenon of the frequently returning patient, and so no 30-days deaths, we think this potential bias does not significantly change our conclusions.

Conclusions
===========

The HSMR model for the Netherlands was sensitive to adjustment for frequency of readmissions. Model 1, without adjustment, compared to model 2, with adjustment, produced substantially different HSMR outcomes. The uncertainty introduced by these differences exceeded the uncertainty indicated by the 95% confidence intervals. Since model 2 turned out to be more accurate compared to model 1 with regard to c-statistics, goodness of fit and explanatory power, the authors would prefer to apply adjustment for frequency of readmission. Parties, also in other countries, making use of HSMR-calculations may decide for themselves whether or not it is clinically relevant in their situation to include frequent admissions in the model. In case of adjustment, a review period of at least three years is advisable.
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